**Hospital-acquired Pneumonia (HAP)**

- **Definition**: Pneumonia developing 48 hours or more post-hospital admission, not incubating at admission.

- **Commonality**: One of the most frequent hospital-acquired infections. Most cases occur in non-ventilated patients, but mechanical ventilation significantly increases risk.

- **Pathogenesis**: Related to microorganism virulence and host response. Infection primarily occurs via microaspiration from colonized oropharyngeal and gastrointestinal tracts.

- **Pathogens**: 
  - **Gram-negative**: Escherichia coli, Klebsiella pneumoniae, Enterobacter spp, Pseudomonas aeruginosa, Acinetobacter spp.
  - **Gram-positive**: Staphylococcus aureus (including MRSA), Streptococcus spp.

### Diagnosis

- **Clinical Diagnosis Recommendations**: 
  - New lung infiltrate + evidence of infectious origin (e.g., fever, purulent sputum, leukocytosis, declining oxygenation).

- **Symptoms**: 
  - Fever, rigor, malaise, anorexia, dyspnoea, cough, purulent sputum, haemoptysis, pleuritic [[chest pain]].

- **Signs**: 
  - Pyrexia (hypothermia in the elderly), cyanosis, confusion, tachypnoea, tachycardia, hypotension, consolidation signs, pleural rub.

- **Risk Factors for HAP**: 
  - Poor infection control, improper bed positioning, intubation/mechanical ventilation, H2 antagonist/antacid use, poor oral hygiene, continuous sedation, reintubation.

### Investigations

- **First-line Investigations**:
  - **Chest X-ray**: Preferred PA and lateral views; look for opacity, diaphragm blurring.
  - **WBC count with differential**: Elevated/decreased counts indicate infection.
  - **Pulse Oximetry**: Values <92% indicate severity.
  - **Sputum Sample**: Non-invasive sampling.

- **Further Investigations**:
  - **Arterial Blood Gas**: To check for hypoxia, respiratory failure, acid-base disturbances.
  - **CT Chest**: For opacity diagnosis and procedure indication.

### Management (Prescribing)

- **Antibiotic Therapy**: Based on local antimicrobial resistance data and MDR risk factors:
  - **MDR Risk Factors**: Previous antibiotics in 90 days, septic shock, ARDS, >5 days hospitalization, acute renal replacement therapy.

- **Adults (≥18 years)**: 
  - **First choice (non-severe)**: Co-amoxiclav.
  - **Alternatives**: Doxycycline, Co-trimoxazole, Levofloxacin, Cefalexin.
  - **Severe symptoms/higher resistance risk**: Piperacillin with tazobactam (alternatives include Ceftazidime, Ceftriaxone, etc.).
  - **MRSA**: Add Vancomycin, Teicoplanin, or Linezolid.

- **Children (<18 years)**: 
  - **<1 Month**: Specialist advice.
  - **1 month and older (non-severe)**: Co-amoxiclav or Clarithromycin.
  - **Severe/higher resistance**: Piperacillin with tazobactam, Ceftazidime, Ceftriaxone.
  - **MRSA**: Add Teicoplanin, Vancomycin, or Linezolid.

### Management (Non-prescribing)

- **Intubation/ventilation**: For respiratory failure.
- **Bronchoscopy/Thoracentesis**: If not improving with treatment or alternative diagnosis needed.
- **Vaccination**: Influenza vaccination recommended to prevent bacterial pneumonia.
- **Hand Hygiene**: Critical for preventing MDR transmission.

### References

1. [UpToDate: Epidemiology, Pathogenesis, Microbiology and Diagnosis](https://www.uptodate.com/contents/epidemiology-pathogenesis-microbiology-and-diagnosis-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults).
2. [UpToDate: Treatment of HAP](https://www.uptodate.com/contents/treatment-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults).
3. Oxford Handbook of Clinical Medicine 9th Ed – Chest Medicine – Pneumonia pg 160.
4. [NICE Guidelines NG139](https://www.nice.org.uk/guidance/ng139/resources/pneumonia-hospitalacquired-antimicrobial-prescribing-pdf-66141727749061).
5. [BMJ Best Practice: HAP Topic](https://bestpractice.bmj.com/topics/en-us/720).